Ubs Group Ag Fulcrum Therapeutics, Inc. Transaction History

Ubs Group Ag

$555 Billion
Q2 2025

A detailed history of Ubs Group Ag transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 135,205 shares of FULC stock, worth $1.29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

135,205

Previous 71,920 87.99%

Holding current value

$1.29 Million

Previous $207,000 349.28%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$2.51 - $7.38 $158,845 - $467,043	63,285 Added 87.99%	135,205 $930,000
Q1 2025 May 13, 2025	SELL	$2.88 - $5.08 $15,759 - $27,797	-5,472 Reduced 7.07%	71,920 $207,000
Q4 2024 Feb 14, 2025	SELL	$2.97 - $4.84 $9,625 - $15,686	-3,241 Reduced 4.02%	77,392 $363,000
Q3 2024 Nov 14, 2024	SELL	$3.18 - $9.74 $349,539 - $1.07 Million	-109,918 Reduced 57.68%	80,633 $287,000
Q2 2024 Aug 13, 2024	BUY	$5.98 - $9.31 $704,342 - $1.1 Million	117,783 Added 161.86%	190,551 $1.18 Million
Q1 2024 May 13, 2024	BUY	$6.7 - $12.0 $285,319 - $511,020	42,585 Added 141.09%	72,768 $686,000
Q4 2023 Feb 09, 2024	BUY	$3.18 - $6.86 $60,502 - $130,518	19,026 Added 170.53%	30,183 $203,000
Q3 2023 Nov 09, 2023	SELL	$3.25 - $6.08 $66,956 - $125,260	-20,602 Reduced 64.87%	11,157 $49,000
Q2 2023 Aug 11, 2023	BUY	$2.26 - $3.8 $70,817 - $119,073	31,335 Added 7390.33%	31,759 $104,000
Q1 2023 May 12, 2023	SELL	$2.83 - $13.99 $9,522 - $47,076	-3,365 Reduced 88.81%	424 $1,000
Q4 2022 Feb 08, 2023	BUY	$5.01 - $8.35 $18,982 - $31,638	3,789 New	3,789 $27,000
Q2 2022 Aug 10, 2022	SELL	$4.2 - $24.0 $6,169 - $35,256	-1,469 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$9.96 - $23.65 $6,414 - $15,230	644 Added 78.06%	1,469 $35,000
Q4 2021 Feb 14, 2022	SELL	$14.0 - $28.44 $6,720 - $13,651	-480 Reduced 36.78%	825 $15,000
Q3 2021 Nov 15, 2021	BUY	$7.28 - $30.97 $2,642 - $11,242	363 Added 38.54%	1,305 $37,000
Q2 2021 Aug 13, 2021	SELL	$8.09 - $12.0 $4,684 - $6,948	-579 Reduced 38.07%	942 $10,000
Q1 2021 May 12, 2021	BUY	$10.94 - $15.32 $13,029 - $18,246	1,191 Added 360.91%	1,521 $18,000
Q4 2020 Feb 11, 2021	SELL	$7.84 - $13.4 $22,704 - $38,806	-2,896 Reduced 89.77%	330 $4,000
Q3 2020 Nov 12, 2020	SELL	$7.22 - $20.7 $8,043 - $23,059	-1,114 Reduced 25.67%	3,226 $26,000
Q2 2020 Jul 31, 2020	SELL	$9.11 - $22.06 $34,372 - $83,232	-3,773 Reduced 46.51%	4,340 $79,000
Q1 2020 May 01, 2020	BUY	$9.49 - $21.26 $19,036 - $42,647	2,006 Added 32.85%	8,113 $97,000
Q4 2019 Feb 14, 2020	BUY	$4.46 - $18.14 $7,421 - $30,184	1,664 Added 37.45%	6,107 $101,000
Q3 2019 Nov 14, 2019	BUY	$6.64 - $14.89 $29,501 - $66,156	4,443 New	4,443 $29,000

Others Institutions Holding FULC

# of Institutions

131

Shares Held

55.5M

Call Options Held

886K

Put Options Held

93.3K

View Full List

About Fulcrum Therapeutics, Inc.

Ticker FULC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,038,900
Market Cap $495M
Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...

More about FULC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account